Ann: March Quarterly Activities Report and Appendix 4C, page-2

Some extracts:

DARRT-2 is an open-label study with a series of interim reporting points, thereby ensuring a reasonably regular news flow


Apart from LuPIN-1, Noxopharm has been making Veyonda available to an international radiotherapy service provider to use it on a compassionate use basis in combination with 177lutetium-PSMA for a significant number of men with late-stage prostate cancer. This use has included in men whose cancer has failed to respond to the 177lutetium-PSMA alone, with Veyonda being used to overcome resistance to 177lutetium-PSMA, a potential major market opportunity


The Company has reported interim data showing that Veyonda to date has proven to be well tolerated (ASX: 5 November 2020) and to be associated with no increase in levels of a broad range of cytokines, including those associated with COVID-19 patients deteriorating and requiring high-level care (ASX: 22 April 2021)